⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23163 | 0.74 | — | — | |
| SCHEMBL27245 | 0.72 | — | — | |
| Trifluoroacetic Acid SCHEMBL1977391 | 0.70 | FFAR3 (0.54) | — | |
| Trifluoroacetic Acid SCHEMBL5242831 | 0.70 | FFAR3 (0.54) | — | |
| Trifluoroacetic Acid SCHEMBL29465551 | 0.70 | FFAR3 (0.54) | — | |
| SCHEMBL14341221 | 0.70 | — | — | |
| SCHEMBL19087049 | 0.70 | — | — | |
| Trifluoroacetic Acid SCHEMBL479935 | 0.70 | FFAR3 (0.54) | — | |
| SCHEMBL21315974 | 0.70 | — | — | |
| Acetic Acid SCHEMBL31314449 | 0.70 | FFAR3 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376819-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-4376830-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-4376829-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| US-20240050456-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREAT-MENT OF CARDIAC DISEASES IN FELINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-02-15 | — | — | US | claimed |
| WO-2023227492-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-30 | — | — | WO | claimed |
| US-20230381101-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-30 | — | — | US | claimed |
| US-20230338406-A1 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-10-26 | — | — | US | claimed |
| EP-3862003-B1 | AN SGLT-2 INHIBITOR FOR USE IN THE TREATMENT OF A METABOLIC DISORDER IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-10-25 | — | — | EP | claimed |
| EP-4245765-A2 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2023-09-20 | — | — | EP | claimed |
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-09-19 | — | — | US | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-6916590-B2 | Resist composition which is excellent particularly in transparency to light beams and dry etching properties and gives a resist pattern excellent in sensitivity, resolution, evenness, heat resistance, etc., as a chemical amplification | ASAHI GLASS COMPANY, LIMITED (JP) | 2005-07-12 | — | — | US | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| US-20030148213-A1 | Resist composition | ASAHI GLASS COMPANY LIMITED (JP) | 2003-08-07 | — | — | US | claimed |
| EP-1302813-A1 | RESIST COMPOSITION | Asahi Glass Company, Limited (JP) | 2003-04-16 | — | — | EP | claimed |
| WO-2002021216-A9 | POLYMERS AND PHOTORESIST COMPOSITIONS COMPRISING ELECTRONEGATIVE GROUPS | SHIPLEY CO LLC (US) | 2003-04-03 | — | — | WO | claimed |
| EP-1268428-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-01-02 | — | — | EP | claimed |
| US-20020058199-A1 | Novel polymers and photoresist compositions comprising electronegative groups | SHIPLEY COMPANY, L.L.C. | 2002-05-16 | — | — | US | claimed |
| WO-2002021216-A2 | POLYMERS AND PHOTORESIST COMPOSITIONS COMPRISING ELECTRONEGATIVE GROUPS | SHIPLEY COMPANY, L.L.C. (US) | 2002-03-14 | — | — | WO | claimed |
| WO-2001077079-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |